<DOC>
	<DOCNO>NCT02103764</DOCNO>
	<brief_summary>The objective present study determine effectiveness cyclic desogestrel ( DSG ) compare cyclic medroxyprogesterone acetate treatment anovulatory dysfunctional uterine bleeding ( DUB ) follow aspect : 1 . Endometrial histopathology change 2 . Menstrual cycle control .</brief_summary>
	<brief_title>Efficacy Cyclic DSG Compared With Cyclic MPA Treatment Anovulatory DUB</brief_title>
	<detailed_description>Anovulatory dysfunctional uterine bleeding ( DUB ) common cause abnormal uterine bleeding especially postmenarcheal adolescent , perimenopausal woman , patient polycystic ovary syndrome ( PCOS ) obese woman . Aims treatment woman anovulatory DUB restore natural control mechanism endometrium ( introduce normal synchronous growth , development , shed structural stable endometrium ) prevent endometrial hyperplasia . The two main treatment option estrogen-progestin therapy progestin therapy . Women sexually active immediately prepared pursue pregnancy best manage estrogen-progestin treatment especially combined oral contraceptive pill ( COCs ) perimenopausal woman , obese woman woman ca n't tolerate COCs contraindication use COCs , cyclic progestin treatment choice . Common use progestin anovulatory DUB medroxyprogesterone acetate ( MPA ) 5-10 mg/day 10-14 day month . This progestin strong progestogenic effect undesirable effect glucocorticoid effect , mineralocorticoid effect androgenic effect . Long term use progestin especially obese woman perimenopausal woman risk diabetes mellitus dyslipidemia may negative effect glucose lipid metabolism . DSG third generation progestin glucocorticoid , mineralocorticoid effect low androgenic effect may better choice treatment data DSG treatment anovulatory DUB u scanty . So study evaluate effect cyclic DSG endometrial histology change lipid , glucose metabolism patient anovulatory DUB . Comparison : Women anovulatory DUB randomize two group , receive course either cyclic DSG cyclic MPA . The main outcome measure compare effect intervention endometrial histology change .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Uterine Hemorrhage</mesh_term>
	<mesh_term>Metrorrhagia</mesh_term>
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Desogestrel</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<criteria>Premenopausal woman anovular DUB ( prove endometrial histology ) Age &gt; 18 yr. Any uterine pathology might cause abnormal uterine bleed Contraindication progestin treatment ( breast cancer ) Severe drug allergy towards progestogen Intake hormonal treatment previous 3 month</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Anovulatory Dysfunctional Uterine Bleeding</keyword>
	<keyword>cyclic desogestrel</keyword>
	<keyword>cyclic medroxyprogesterone acetate</keyword>
	<keyword>lipid metabolism</keyword>
	<keyword>glucose metabolism</keyword>
	<keyword>endometrial histology change</keyword>
</DOC>